LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis

Brief summary (registry, in English)

Reduction of mortality in multi-system (ms)-LCH by early switch to salvage treatment of patients with risk organ involvement and without response to 1st-line therapy. Randomized investigation of prolongation or intensification of continuation therapy to reduce reactivations and late sequelae in ms-LCH. Randomized investigation to reduce reactivation rate, late sequelae by prolongation of continuation therapy (6 vs. 12 m) in single-system (ss)-LCH with isolated "CNS-Risk" lesion or multifocal bone (mfb) lesions. Investigation to achieve disease resolution, prevent reactivations, late sequelae in non-risk organ involvement patients with 2nd-line treatment (PRED/ARA-C//VCR) for 24 weeks followed by continuation therapy (Indomethacin vs. 6-MP/MTX) for 24 months in total.

What you commit to

• Study type: Interventional · Phase 2/3
• Planned participants: 1124
• 84 sites in 12 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.

Who cannot take part

Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: - to 17 years · Sex: All · Does not accept healthy volunteers

Full criteria on EU CTIS (euclinicaltrials.eu)

Sites (84)

Sites in registry order. Pick your city on the disease page to sort them by distance.